INTRODUCTION
Cadmium (Cd) is an environmental and industrial pollutant that poses a serious health risk to humans and animals. Cd 2+ has multiple cytotoxic and metabolic effects, such as interfering with the normal actions of essential metals, 1) inducing oxidative stress, 2) and altering the activities of various enzymes. 3, 4) After Cd exposure, Cd is distributed mainly to the liver and kidneys and accumulates with metallothionein (MT). MT is a small metal-binding protein that is characterized by its high thiol content: 20 of its 61 amino acids are cysteine, all of which are in the reduced state and are involved in its metal binding properties. MT-I transgenic mice are resistant to Cd-induced lethality and hepatotoxicity. 5) In comparison, MT-null mice show increased susceptibility to Cd-induced lethality and liver injury, and lack Cd accumulation. 6 ) MT may sequester Cd 2+ from molecular targets by binding to Cd 2+ with high affinity and thus making it less available for excretion. Therefore, with chronic exposure to Cd 2+ at non-acute toxic doses, MT appears to accumulate Cd in a less toxic form until reaching the critical level. 7, 8) Conversely, if, under certain conditions, Cd 2+ is released from its bond with MT, Cd toxicity may appear again.
MT recently has received increased attention due to its ability to act as a scavenger of free radicals. 9, 10) Hydrogen peroxide and free radicals induce loss of the metal-binding properties of MT by oxidation of its thiol residues. 11) In addition, the affinity of Cu for the metal-binding sites on MT is substantially greater than that of Zn or Cd.
12) Therefore, we studied here in vitro and in vivo whether Cd 2+ could be released from its binding to MT after oxidative stress and treatment with Cu 2+ to become toxic again.
No. 3 (0.9 µg) in 10 mM Tris-HCl (pH 7.4). After incubation, all reaction mixtures were applied to a Sephadex G-75 column (1.5 × 28 cm) equilibrated with 10 mM Tris-HCl (pH 8.0). The column was eluted with the same buffer, and 2-ml fractions were collected. Release of Cd or Zn from Binding to MT after an Injection with Fe-NTA to Cd-MT or Zn-MT Accumulated Mice ---Mice were pretreated with CdCl 2 (1 mg Cd/kg once daily subcutaneously for 6 days) or with ZnSO 4 (20 mg Zn/kg once daily subcutaneously for 2 days). The aim was to accumulate Cd-MT or Zn-MT; these mice are here after referred to Cd-MT and Zn-MT accumulated mice, respectively. Two days after the last injection, Cd-MT or Zn-MT accumulated mice were injected subcutaneously with Fe-NTA (7.5 mg/kg). After 4 hr, mice were euthanized by over-anesthesia. The kidneys were obtained and homogenized with 10 mM TrisHCl (pH 8.0). The concentration of Cd bound to MT was determined by using the Cd-hem method as described previously.
MATERIALS AND METHODS

Animals
13)
Activity of Superoxide Dismutase (SOD) in Mouse
Cytosol Incubated with Cd Released from Cd-MT ---Cytosol was prepared from intact mouse livers. Incubation mixtures of purified Cd-MT (100 µg as Cd) with 10 mM H 2 O 2 or Cu 2+ (30 µg) were concentrated by lyophilization to remove excess H 2 O 2 and then were filtered by Ultrafree-MC 5000 (Millipore Co., Billerica, MA, U.S.A.) to remove MT. These filtrates contained only Cd 2+ , and not Cu 2+ . After either purified Cd-MT or these filtrates was added to mouse cytosol, the SOD activity in each of these cytosol was measured using the inhibition of nitroblue tetrazolium (NBT) reduction due to superoxide anion generation by xanthine plus xanthine oxidase (NBT method).
14)
Simultaneous Injection with Cu 2+ and Cd 2+ to Cd-MT or Zn-MT Accumulated Mice ---Seven days (Cd-MT accumulated mice; 1 mg/kg daily for 6 days) or 1 day (Zn-MT accumulated mice; 20 mg/ kg daily for 6 days) after the last injection with Cd or Zn to mice, various doses of Cu 2+ (0-2 mg/kg) were injected intravenously with or without CdCl 2 (0.8 mg Cd/kg). After 4 or 24 hr, mice were euthanized by over-anesthesia. Heparinized blood was collected. The activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in plasma were determined spectrophotometrically by using Transaminase CII-Test kits (Wako Pure Chemical Industries, Ltd.). After sections of liver was homogenized with 0.25 M sucrose, the tissue homogenates were digested with nitric acid overnight, and the concentrations of Cd and Cu were analyzed using flame atomic absorption spectrophotometry (AAS; Z-5000 Polarized Zeeman Atomic Absorption Spectrophotometer, Hitachi, Tokyo, Japan). Cytosol prepared from the homogenates of liver after 4 hr was applied to Sephadex G-75 columns under the same conditions as for the in vitro study. Statistical Analysis ---Results are expressed as mean ± 1 standard deviation (S.D.). Data were analyzed for significance by using Student's t-test and by a two-tailed analysis of variance (ANOVA). Differences were considered significant at p < 0.05. Figure 1 shows the gel filtration profiles of (Fig. 1C) resulted in a decrease of Cd concentration in MT fraction and an increase of Cd concentration in low-molecular-weight (LM) fraction. Further, injection with Fe-NTA caused a decrease in the concentration of Zn or Cd bound to renal MT in Zn-MT or Cd-MT accumulated mice, respectively (Fig. 2) . These data indicate that reactive oxygen species and some metals whose affinity for MT is higher than that of Cd can cause the release of Cd 2+ from Cd-MT in vivo.
RESULTS
Release of Cd from Binding to MT
In Vitro Inhibition of Cytosolic SOD Activity by Cd Released from Cd-MT Figure 3 shows the activity of cytosolic SOD after incubation of Figure 4 shows the plasma activities of ALT (A) and AST (B) after simultaneous injection with Cu 2+ (0-2 mg/kg) and Cd 2+ (0.8 mg/kg) to Cd-MT accumulated mice. Though an injection with Cu 2+ or Cd 2+ alone did not elevate the plasma activities of ALT and AST, simultaneous injection with Cu 2+ at a higher dose than 0.75 mg/kg and Cd 2+ resulted in a marked increase in both enzyme activities, indicating liver injury. Figure 5A shows the hepatic concentrations of Cd and Cu after simultaneous injection with Cd and various doses of Cu 2+ . The hepatic concentration of Cu, but not Cd, increased with increasing Either Cd-MT (1 mg/kg daily for 6 days) or Zn-MT (20 mg/kg daily for 2 days) accumulated mice were injected with saline or Fe-NTA (7.5 mg Fe/kg); 4 hr later, the kidneys were obtained and the renal Cd and Zn concentrations were determined. Data points represent mean ± S.D. (n = 4). **, p < 0.01 versus saline mice. the release of Cd from accumulated Cd-MT. In contrast, simultaneous injection of Zn-MT mice with Cu 2+ and Cd 2+ did not induce hepatic injury (Fig. 6 ). These results suggest that Cd released from accumulated Cd-MT by simultaneous injection of Cd-MT accumulated mice with Cu 2+ and Cd 2+ may participate in development of hepatic injury.
DISCUSSION
The Cd accumulated in target organs (e.g., liver, kidney) is not toxic until it reaches each critical Cd concentration after chronic Cd exposure. 7, 8) Most of the Cd is accumulated with MT in the cell; therefore, MT may sequester Cd 2+ from molecular targets by binding to Cd 2+ with high affinity. Even if treatment with a hepatoxin or nephrotoxin induces the redistribution of Cd accumulated in the liver and kidney to the plasma, the Cd is transferred along with MT.
15) However, we demonstrated here in vivo that Fe-NTA induced the release of not only Zn from its binding to MT, but also MT-bound Cd. Maret suggests that release of the biologically redox-insert Zn 2+ follows reaction of the redox-active cysteine sulfur ligand with an oxidant. 16) Whereas Zn 2+ plays essential roles in almost all aspects of metabolism, the Cd released from Cd-MT may appear to toxic action again. Our in vitro study shows that the Cd released from Cd-MT inhibited the cytosolic 
17)
It is well known that Cu and Hg have higher affinity for MT than do Cd and Zn. 12) In the present data, addition of Cu 2+ to Cd-MT led to release of Cd from MT in vitro. However, injection of Cd-MT accumulated mice with various doses of Cu 2+ did not induce hepatotoxicity. Because accumulated MT contained not only Cd but also Zn in Cd-MT accumulated mice, the amount of Cd released from Cd-MT may not have been enough to induce hepatotoxicity. Interestingly, simultaneous injection with Cu 2+ and Cd 2+ caused hepatic injury in Cd-MT accumulated mice but not Zn-MT mice, whereas injection with a similar dose of Cu 2+ or Cd 2+ alone failed to induce hepatotoxicity. Moreover, simultaneous injection with Cu 2+ and Cd 2+ led to a decrease in the concentration of Cd in hepatic MT fraction of Cd-MT accumulated mice. These data suggest that the Cd released from accumulated Cd-MT may be concerned to initiate hepatotoxicity after simultaneous injection with Cu 2+ and Cd 2+ to Cd-MT accumulated mice.
Although many reports suggest that Cu-MT is a prooxidant, 18) overexpression of MT in cells after Cd pretreatment, or ectopic overexpression by gene transfer, confers protection from Cu-dependent lipid oxidation and cytotoxicity. Conversely, when MT is depleted (e.g., by actinomycin D), the concentration The ALT activity in the plasma was determined 24 hr after simultaneous injection with Cu 2+ (1 mg/kg) and Cd 2+ (0.8 mg/kg) or an injection with saline to Zn-MT (20 mg/kg daily for 6 days) or Cd-MT (1 mg/kg daily for 6 days) accumulated mice. Data points represent mean ± S.D. (n = 4). *, p < 0.05 versus saline.
of non-MT-associated, 'free' cytosolic Cu 2+ is elevated, and hepatoma tissue culture cells rapidly lose their resistance to Cu toxicity, as reflected in loss of cell viability. 19) Therefore, binding of Cu to MT appears to render Cu redox-inactive, but oxidation of free thiols critical for metal binding can reduce MT/ Cu interactions and potentiate Cu redox cycling. 18) If Cu is released from accumulated MT in Cd-MT accumulated mice, this free Cu in turn might enhance the release of Cd from its binding to MT.
We propose that oxidative stress and contamination with metals whose affinity for MT is higher than that of Cd may cause toxicity due to the release of Cd from its binding to MT by thiol oxidation and metal replacement. Even if the amount of Cd accumulated in human tissues is lower than the critical level, 20) the actual concentration of accumulated Cd may be a risk factor for Cd toxicity under some conditions.
